Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Early and late risk of ischemic stroke after TAVR as compared to a nationwide background population

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cardiac MRI quantitative tissue characterization of right atrial mass using mDixon and parametric mapping

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Aortic events in a nationwide Marfan syndrome cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Impact of the learning curve on outcome after transcatheter mitral valve repair: results from the German Mitral Valve Registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Ischemic stroke is a feared complication associated with transcatheter aortic valve replacement (TAVR). Data on the late risk of ischemic stroke following TAVR are scarce. This study aimed to investigate the early (0-90 days) and late (90 days-5 years) risk of ischemic cerebrovascular events (CVE) in a large, unselected cohort of patients undergoing TAVR and to compare this risk with a matched background population. Therefore, all patients undergoing first-time TAVR in Denmark were matched to a background population (controls) in a 1:4 ratio based on age, sex, atrial fibrillation (AF), and the major stroke risk factors. A total of 2455 TAVR patients were matched with 9820 controls. TAVR was associated with a significantly higher ischemic CVE risk as compared with their controls in the early phase [hazard ratio (HR) 5.35 [95% CI 3.50-8.17]; p < 0.001) but not in the late phase (HR 1.17 [95% CI 0.94-1.46]; p = 0.15). In a predefined stratified analysis, no patient-related factors were associated with this higher CVE risk in the early phase. The cumulative 90-day ischemic CVE risk was the lowest in TAVR-patients with known AF receiving oral anticoagulant (OAC) therapy (1.3% [95% CI 0.6-2.5%] and was two-fold higher in OAC-naïve TAVR-patients (2.4% [95% CI 1.8-3.3%] in patients without AF and 2.5% [95% CI 0.9-5.3%] in patients with AF). In conclusion, TAVR was associated with an increased risk of ischemic CVE in the early phase, but not in the late phase, as compared to their matched controls-OAC therapy reduced this early risk of ischemic CVE by half.

Original languageEnglish
JournalClinical research in cardiology : official journal of the German Cardiac Society
ISSN1861-0684
DOIs
Publication statusE-pub ahead of print - 30 Oct 2019

    Research areas

  • Anti-thrombotic treatment, Aortic valve replacement, Cerebrovascular event, Transcatheter

ID: 58441505